Meeting
2015 ASCO Annual Meeting
Phase I study of vorinostat combined with isotretinoin and temozolomide in adults with recurrent malignant gliomas.
Authors
Marta Penas-Prado
The University of Texas MD Anderson Cancer Center, Houston, TX
Marta Penas-Prado , Kenneth R. Hess , Victor A. Levin , John Frederick De Groot , Howard Colman , Morris D. Groves , Charles A. Conrad , Monica Elena Loghin , Kathy Hunter , Mark R. Gilbert , W. K. Alfred Yung , Vinay K. Puduvalli
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Central Nervous System Tumors
Track
Central Nervous System Tumors
Sub Track
Central Nervous System Tumors
Clinical Trial Registration Number
NCT00555399
Citation
J Clin Oncol 33, 2015 (suppl; abstr 2039)
DOI
10.1200/jco.2015.33.15_suppl.2039
Abstract #
2039
Poster Bd #
28
Abstract Disclosures
Similar Posters
Poster
2019 ASCO Annual Meeting
Phase I study of procaspase activating compound -1 (PAC-1) in combination with temozolomide (TMZ) for the treatment of recurrent malignant glioma.
First Author: Martin Kelly Nicholas
Poster
2019 ASCO Annual Meeting
Phase I trial of TG02 plus dose-dense or metronomic temozolomide for recurrent anaplastic astrocytoma and glioblastoma in adults.
First Author: Jing Wu
Poster
2017 ASCO Annual Meeting
Phase I trial of dimethyl fumarate, temozolomide, and radiation therapy in glioblastoma multiforme.
First Author: Danielle A. Shafer
Poster
2016 ASCO Annual Meeting
Phase I/II study of VAL-083 in patients with recurrent glioblastoma.
First Author: Kent C. Shih